CTLA4 and cancer: In patients with other cancers, GI AEs are more likely with regimens containing an anti- cytotoxic T-lymphocyte-associated protein 4 (CTLA4) agent and less likely with anti-PD-1 or -PD-L1 monotherapy.55,56